Cartalax
Ala-Glu-Asp (AED)
Cartalax is the synthetic tripeptide Ala-Glu-Asp, one of the Khavinson 'peptide bioregulators', marketed for cartilage and connective tissue.
Regulatory status: Not a medicine anywhere. No regulator has approved it and no clinical trial of it has been published.
Default vial
10 mg
Default mix
2 mL
Reported range
No published human dose
Draw (U-100)
20 u
A tripeptide, Ala-Glu-Asp. Not the same compound as Epitalon, which is the tetrapeptide Ala-Glu-Asp-Gly — nearly all the published 'AED' literature is actually about Epitalon. Almost nothing studies AED itself.
Where these numbers come from
No published study reports a dose for this compound in people. The figures here exist only so the calculator can run — they are not a recommendation. Only one published study tests Ala-Glu-Asp itself, in cultured fibroblasts — the rest of the "AED" literature is about Epitalon, a different peptide.
Reviewed October 2026
What it is
- A three-amino-acid peptide: alanine, glutamic acid, aspartic acid (AED).
- Not the same compound as Epitalon, which is the four-amino-acid Ala-Glu-Asp-Gly (AEDG). The two are routinely conflated, including in search results, because the shorter sequence is contained in the longer one.
- Proposed by its originators to act as a short regulatory peptide influencing gene expression.
- Sold as a research compound; no established route or schedule.
How it is described to act
- 1
No pharmacokinetic study of this peptide in people has been published, so how it is absorbed, distributed or cleared is unknown.
- 2
Short peptides of this kind are generally broken down quickly by peptidases, which is a recognised difficulty for the class.
- 3
The proposed mechanism is direct interaction with DNA or chromatin to influence transcription — a hypothesis from the originating group, not a demonstrated pathway.
- 4
No outcome has been measured in a person.
What the research has looked at
What actually studies AED
- A 2016 paper in Bulletin of Experimental Biology and Medicine reported on peptides AED and AEDG in cultured human skin fibroblasts — the clearest published work naming AED itself.
- Beyond that, searches for 'Ala-Glu-Asp' return studies of Epitalon (AEDG), a different compound that Pep-Tidy lists separately.
What the literature is not
- There is no published human trial of Cartalax.
- The available work comes from a single research tradition and has not been independently replicated outside it.
Strength of evidence: Preclinical evidence only
One cell-culture paper names this peptide. Everything else commonly cited for it is research on Epitalon, a different molecule.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- No human safety data exists.
- Because the literature is routinely conflated with Epitalon, safety claims made for 'AED' are frequently borrowed from a compound the buyer is not taking.
References
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
Cartalax questions people ask
How do you reconstitute Cartalax?
A common starting point for a 10 mg vial of Cartalax is 2 mL of bacteriostatic water, which gives 5 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of Cartalax is one dose?
At 5 mg per mL, that works out to about 20 units on a U-100 insulin syringe for a 1000 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for Cartalax?
Published and community sources describe No published human dose, subcutaneous, every day, typically run 0 weeks on. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should Cartalax be stored?
Lyophilized Cartalax vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.